ArticleClinical lymphoma, myeloma & leukemia2019

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma.

Sikander Ailawadhi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.